D
David Molkentine
Researcher at University of Pittsburgh
Publications - 34
Citations - 737
David Molkentine is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Head and neck squamous-cell carcinoma & Radiosensitivity. The author has an hindex of 14, co-authored 28 publications receiving 619 citations. Previous affiliations of David Molkentine include University of Texas at Austin & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Heath D. Skinner,Uma Giri,Liang P. Yang,Manish Kumar,Ying Liu,Michael D. Story,Curtis R. Pickering,Lauren Averett Byers,Michelle D. Williams,Jing Wang,Li Shen,Suk Young Yoo,You Hong Fan,David Molkentine,Beth M. Beadle,Raymond E. Meyn,Jeffrey N. Myers,John V. Heymach +17 more
TL;DR: The data point to a targetable Axl–PI3 kinase–PD-L1 axis that is highly associated with radiation resistance, and patients with PD-L 1 low/CD8+ tumor-infiltrating lymphocytes high had no local failure or death due to disease.
Journal ArticleDOI
DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy
Benjamin J. Moeller,John S. Yordy,Michelle D. Williams,Uma Giri,Uma Raju,David Molkentine,Lauren Averett Byers,John V. Heymach,Michael D. Story,J. Jack Lee,Erich M. Sturgis,Randal S. Weber,Adam S. Garden,K. Kian Ang,David L. Schwartz +14 more
TL;DR: Ku80 overexpression is a common feature of HNSCC, and is a candidate DNA repair-related biomarker for radiation treatment failure and death, particularly in patients with high-risk HPV-negative disease.
Journal ArticleDOI
Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro
Daisuke Sano,Fumihiko Matsumoto,David Valdecanas,Mei Zhao,David Molkentine,Yoko Takahashi,Ehab Y. Hanna,Vassiliki A. Papadimitrakopoulou,John V. Heymach,Luka Milas,Jeffrey N. Myers +10 more
TL;DR: The combination treatment with vandetanib, cisplatin, and radiation was superior to the rest of treatments in antitumoral effects, prolonging survival, decreasing cervical lymph node metastases in vivo and increased both tumor and tumor-associated endothelial cell apoptosis and decreased microvessel density in vivo.
Journal ArticleDOI
Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer
Heath D. Skinner,Uma Giri,Liang Yang,Sang Hyeok Woo,Michael D. Story,Curtis R. Pickering,Lauren Averett Byers,Michelle D. Williams,Adel K. El-Naggar,Jing Wang,Lixia Diao,Li Shen,You Hong Fan,David Molkentine,Beth M. Beadle,Raymond E. Meyn,Jeffrey N. Myers,John V. Heymach +17 more
TL;DR: Proteomic analysis identified PTK2/FAK overexpression is a biomarker of radioresistance in locally advanced HNSCC, and PTK 2/ FAK inhibition radiosensitized HNS CC cells and Combinations of PTK1/FAk inhibition with radiotherapy merit further evaluation as a therapeutic strategy for improving local control in HPV-negative HNScc.
Journal ArticleDOI
Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways
Uma Raju,Oliver Riesterer,Zhi Qiang Wang,David Molkentine,Jessica M. Molkentine,Faye M. Johnson,Faye M. Johnson,Bonnie S. Glisson,Luka Milas,K. Kian Ang +9 more
TL;DR: It is demonstrated that dasatinib induces apoptosis and blocks DNA repair in EGFR-expressing HNSCC cells and improves radiotherapy outcome, and warrant further investigation using in vivo tumor models for potential translation into clinical testing.